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Abstract: Alzheimer’s disease (AD) is an age-related disease caused by abnormal accumulation
of amyloid-β in the brain leading to progressive tissue degeneration. Flurbiprofen (FP), a drug
used to mitigate the disease progression, has low efficacy due to its limited permeability across
the blood–brain barrier (BBB). In a previous work, FP was coupled at the uppermost branching of
an ε-lysine-based branched carrier, its root presenting a phenylalanine moiety able to increase the
hydrophobicity of the complex and enhance the transport across the BBB by adsorptive-mediated
transcytosis (AMT). The present study explores a different molecular design of the FP-peptide delivery
system, whereby its root presents an ApoE-mimicking peptide, a targeting ligand that could enhance
transport across the BBB by receptor-mediated transcytosis (RMT). The functionalised complex was
synthesised using a solid-phase peptide synthesis and characterised by mass spectrometry and FTIR.
Cytotoxicity and permeability of this complex across an in vitro BBB model were analysed. Moreover,
its activity and degradation to release the drug were investigated. The results revealed successful
synthesis and grafting of FP molecules at the uppermost molecular branches of the lysine terminal
without observed cytotoxicity. When covalently linked to the nanocarrier, FP was still active on
target cells, albeit with a reduced activity, and was released as a free drug upon hydrolysis in a
lysosome-mimicking medium. Noticeably, this work shows the high efficiency of RMT-driven FP
delivery over delivery systems relying on AMT.
Keywords: Alzheimer’s disease; neurodegenerative diseases; blood–brain barrier; ApoE-peptide;
drug delivery system; flurbiprofen
1. Introduction
Alzheimer’s disease (AD) is an uncurable age-related neurodegenerative disease (ND) leading
to a progressive loss of memory and cognition for which the incidence is exacerbated in an ageing
population [1–3]. The main pathological hallmarks of the disease are abnormal aggregates of toxic
extracellular deposits of beta-amyloid (Aβ) peptides and tau amyloid proteins in the brain [4].
Aβ species are generated from the amyloid precursor protein (APP) via sequential proteolytic cleavages
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mediated by γ-secretase enzyme. The fragments of APP are made up of different Aβ isoforms
depending on the number of amino acids [5]. The most prevalent isoforms of Aβ are Aβ40 and Aβ42
which, in AD, form dense clumps of deposits surrounding neurons and giving rise to senile plaques
(SP) of ND [6]. In healthy individuals, the Aβ peptide level remains at a steady state and does not lead
to the generation of amyloid plaques due to metabolism of the peptides [7].
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as Flurbiprofen (FP) have been considered
in the treatment of AD because of their activity as γ-secretase modulators (GSMs) [8]. FP is able to
reduce Aβ42 levels by selectively controlling the γ-secretase activity without remarkable impediment
to the Notch signalling or other pathways of APP processing [9]. This selective action mode brings
significant clinical advantages when compared to nonselective γ-secretase inhibitors, which can affect
the metabolism of total amyloid proteins that regulate many neuronal and synaptic functions [10].
In addition, FP is an FDA-approved drug, commercially used for pain relief and anti-inflammatory
action [11]. The drug is well-absorbed within a 4-h biological half-life and is fully excreted from the
body within 24 h [12]. However, FP has a low BBB penetration and the reached concentration at the
target brain tissue is below the required therapeutic concentration (150−250 µM) reported to exert a
significant pharmacological effect on the γ-secretase activity [13,14].
Various approaches have been developed to enhance the BBB permeability towards FP, including
invasive techniques, chemical modifications, and enhanced permeability of the endothelial cells of
the BBB via endogenous transcytosis [15]. In particular, adsorptive mediated transcytosis (AMT) and
receptor-mediated transcytosis (RMT) have been considered as the most favourable ones to enhance
drug transport without damaging the BBB cells [16]. AMT allows essential circulating hydrophobic
molecules to enter the brain via charge interaction between positively charged molecules and negative
charges on the cell membrane [17]. Our previous work has demonstrated the ability of a peptide-based
nanocarrier to enhance FP transport across brain endothelial cells by AMT when a hydrophobic
phenylalanine moiety was integrated with a lysine and where FP molecules were covalently coupled
to the two amino terminals of the latter [18].
However, RMT, through a specific receptor of the BBB endothelial cells, has been shown to provide
more selective and active targeting [19]. Different macromolecules and drug-laden nanocarriers
have been shown to be efficiently transported by this approach [16,20,21], particularly exploiting the
enhanced expression of these specific receptors by the endothelial cells of the BBB [21–23].
There are various potential endogenous receptor systems that have been exploited for a range of
applications including the insulin receptor, but this is considered the riskiest approach as its mechanism
interferes with glucose homeostasis [15,24]. An alternative receptor target is the transferrin (Tf) receptor
(TfR), which mediates the transport of TF-bound iron that has been exploited to transport drugs
across the BBB either by using Tf as a ligand or by using a specific antibody (such as OX26) [25].
However, Tf’s relatively high molecular weight and limitations in its scaled-up synthesis hinder its use
in pharmaceutical formulations [15]. The diphtheria toxin receptor is another transmembrane receptor
with no particular endogenous ligand, but it is not widely used because of its toxicity [15,26].
Currently, the most widely targeted receptor to deliver drugs or genes to the brain is the
low-density lipoprotein receptor (LDLr) for the respective Proteins 1 and 2 (LRP1r and LRP2r), as they
are upregulated on the BBB endothelia when compared to other types of tissue cells [27–30]. Extensive
studies have been performed on the interaction of this receptor with ApoE when expressed by brain
endothelia, and it has been demonstrated that nanoparticles (NPs) decorated with ApoE have a higher
BBB penetration through LDLr-mediated transcytosis [31]. In particular, a specific amino acid sequence
of ApoE has been identified as promoting the RMT thus becoming a suitable candidate for BBB RMT
nanocarriers [32–35].
This binding sequence of the ApoE has been investigated in various studies [36,37], and it was
initially found that the amino acid sequence (141-155) can indeed be recognised by the LDLr [38].
A shorter sequence (i.e., 141-150, -LRKLRKRLLR-) has been shown to induce endocytosis via
LDLr-engagement using primary neuronal cultures of brain tissue [39]. The endocytosis process
Nanomaterials 2020, 10, 1590 3 of 18
of this sequence has been further investigated via electron and fluorescence microscopy and found
to be able to interact with the LDLr [33]. The decoration of liposomes with this peptide sequence
(141-150) has been efficiently shown to be taken up by the brain endothelium of rats [33]. Different
carrier systems, such as nanoliposomes (NLs), to deliver drugs were successfully synthesised and
functionalised with the ApoE-derived residue and evidently enhanced the brain uptake of antioxidant
drugs and curcumin [32,34].
Our previous work has demonstrated that this sequence can enhance the uptake of a
peptide-based nanocarrier by brain endothelial cells [40]. The study showed that the ApoE-mimicking
sequence—LRKLRKRLLR—could be modified by lysine monomers exposing amino terminal branches
able to enhance drug coupling and targeting brain endothelial cells via RMT.
Capitalising on these previous studies, the present work shows the optimised method of designing
a G0 ApoE-derived peptide (AEP) delivery system to which two FP molecules were coupled at the two
lysine amino terminals to improve the bioavailability of the drug at brain tissue. The work showed
that this drug delivery system has no cytotoxicity and could exert FP inhibition on the γ-secretase
activity of neuroglial cells, either when the drug was still coupled to the peptide carrier or when
released through hydrolysis in a medium mimicking that of the lysosomes. Noticeably, the transcytosis
of FP across a brain endothelium model was enhanced in comparison to that observed for both the
free drug and an AMT-driven FP peptidic nanocarrier [18,40]. The aim of this study is, therefore,
to design a biocompatible and biodegradable drug delivery system able to carry a higher FP payload
across the BBB and release it at the target (brain tissue), with prospective optimal bioavailability and a
concentration that should minimise side effects seen with current high-dose therapy in the treatment
of AD.
2. Materials and Methods
2.1. Design and Synthesis of the RMT-Driven (AEP-Functionalised)-FP Delivery System
The RMT-driven-FP delivery system was designed by modifying the ApoE-mimicking sequence,
H-LRKLRKRLLR-OH, with the addition of a lysine (K) at its amino terminal and coupling two FP
molecules to the two exposed amino groups of the lysine. The complex AEP-lysine-FP delivery
system (AEP-K-FP) (chemical formula: C96H152 F2N26O14, molecular weight (MW): 1932 Da (Figure 1)
was obtained by a solid phase peptide synthesis (SPPS) method, where the yield of the reaction
was enhanced by the aid of microwave synthesiser Biotage Initiator (Hengoed, UK) [41]. All amino
acids, Rink amide, and Tenta gel used were obtained from Merck Ltd. (Southampton, UK) (purity
98%), and other solvents of high-performance liquid chromatography (HPLC) grade were purchased
from Fisher Scientific (Loughborough UK). The assembly started on a Tenta gel NH2 resin (0.5 g)
using 0.4 mmol of phenylalanine (Fmoc-Phe-OH) and a sequence of Fmoc-Leu-OH, Fmoc-Arg-OH,
Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Arg-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg-OH, Fmoc-Leu-OH,
Fmoc-Leu-OH, Fmoc-Arg-OH, consecutively followed by the coupling of lysine (Fmoc-Lys(Fmoc)-OH)
and FP (Sigma Aldrich, Gillingham, UK) [40].
In particular, the synthesis process included a series of coupling and deprotection for
each added amino acid. For each amino acid coupling, 0.4 mmol N-[1H-benzotriazol-1-yl)-
(dimetylamino)methylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HBTU), 140 µL
N,N–diisopropylethylamine (DIPEA), and 3 mL N, N–dimethylformamide (DMF) were added and
sonicated for solubilisation. However, the deprotection that removes the Fmoc group involved
the addition of 3 mL solution of 20% v/v piperidine/DMF [42]. Furthermore, a capping step was
added during the synthesis to remove any unreacted amino groups or separated truncated sequences
that might be formed after the coupling steps, so the loading of the resin could also be reduced.
The capping is achieved by treating the peptide when still on the resin, after coupling, with a high
excess (approximately 50-fold molar) of a reactive derivative of acid and a base [43]. In this work,
when the coupling solution was completed, the capping step was performed according to a previously
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published method [44]. When all amino acids were coupled, the two FP molecules were covalently
grafted to the lysine amino terminal using the same method used for deprotected amino acids.
After that, the synthesised molecule was cleaved from the resin using a cocktail solution of 95%
trifluoroacetic acid, 2.5% triisopropylsilane, and 2.5% (v/v) deionised water. The cleaved mixture was
then filtered, collected, and purified from any undesired by-products by Zeba spin desalting columns
(Fisher Scientific, Loughborough, UK). The final pure product was stored dry at −20 ◦C until used for
all the subsequent experiments.Nanomaterials 2020, 10, x FOR PEER REVIEW 4 of 18 
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2.2. Characterisation of the AEP-Functionalised FP-Delivery System
2.2.1. Mass Spectrometry
The synthesised delivery system was characterised by electrospray/ionisation time-of-flight
(ESI-TOF MS) (Bruker Daltonics, Coventry, UK) at high voltage (4 kV). In this mode, sample mass (m/z)
gives rise to multiple-charged ions associated with charges (n) as (MW + nH)/n, (H is re resente as
mass of proto = 1.008Da).
2.2.2. Fourier Transform Infra-Red (FTIR)
FTIR spectrosc py (Perkin Elmer Spectrum 65, Llantrisant, UK) was used to investigate
structural and fu ctional group chang s in the synthesised complex using a few milligrams f the
sample via 32 scans in the ra ge 550–4000 m−1.
2.3. Preparation of Cultured Cells
2.3.1. bEnd.3 Cells
Immortalised brain endot elial cells, bEnd.3 ( assages 15–20), were cultured, according to
the (manufacture ATCC) product sheet, in a Dulbecco’s modified eagle’s medium (DMEM) high
glucose medium with L-pyruvate, containing 10% (v/v) foetal bovine serum (FBS) and 1% (v/v) of
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500 U/mL Penicillin/Streptomycin (Gibco, Gaithersburg, MD, USA). Cells were seeded at a density of
5 × 104 cells per cm2 in 24-well plates, which were incubated at 37 ◦C and 5% CO2 with replacement
of the culture media every 3 days.
2.3.2. Human Umbilical Vein Endothelial Cells
The synthesised AEP-K-FP was also tested on human umbilical vein endothelial cells (HUVECs)
(ATCC- Manassas, VA, USA) (passages 35 to 39). HUVECs were routinely cultured in an endothelial
basal medium (F-12K) containing 0.05 mg/mL of endothelial cell growth supplement (ECGS), 0.1 mg/mL
of heparin (Gibco Gaithersburg, MD, USA) and adjusted to a final concentration of 10% v/v of FBS
(according to the manufacturer’s recommendations).
2.3.3. Preparation of C6 Glial Cells
C6 glial cells (ATCC-) (passages less than 20) were seeded using the complete growth medium,
which was made according to the ATCC product sheet by addition of FBS to a final concentration of
2.5% v/v and horse serum (Gibco Gaithersburg, MD, USA) to a final concentration of 15% v/v to F-12K
medium. Experiments were performed when cells reached confluence.
2.4. Cytotoxicity Assays
Experiments were performed when cells reached confluency and a range of concentrations
(25 to 400 µM) of AEP-K-FP were used in each experiment. The 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrozolium bromide (MTT) assay (Sigma Aldrich, Gillingham, UK) was used to measure
cell viability [45]. After 24 and 48 h of treatment exposure, the absorbance was measured at a
wavelength of 540 nm in a spectrophotometer (Thermo Multiskan Ascent, Rochford, UK). Readings
were expressed as a percentage of the untreated control cells.
The lactate dehydrogenase (LDH) assay provides an indication of loss of cell membrane
integrity and was measured using a Promega CytoTox96® nonradioactive cytotoxicity assay kit
(Southampton, UK) after 24 and 48 h of treatment. Absorption was read spectrophotometrically at 492
nm and converted to a percentage of the total LDH released from the positive control (untreated cells
with complete lysis).
For cell death assessment, Hoechst 33342 and propidium iodide (PI) salt (HPI) was used
(Sigma-Aldrich, Gillingham, UK). These intracellular dyes stain cells in which the Hoechst 33342
binds to DNA, so it is staining the nuclei, whereas PI stains the cytoplasm, resulting in emission of
light observed under a fluorescent microscopy [46]. Live cells appear blue with intact membranes
on microscopic examination, and those at early and late apoptotic phases appear bright blue with
shrinkage. On the other hand, necrotic or damaged cells appear red with ruptured membranes [47].
HPI dye was prepared by adding 900 µL of DMEM to a mixture solution of 50 µL of 1mg/mL
Hoechst 33342 and 50 µL of 2 µg/mL PI in a glass vial. After 24 h of treatment and incubation, which
were performed as previously discussed [44], an epi fluorescent microscopy (Olympus microscope
equipped with a Nikon D1X camera, UK) was used to identify and count the cells with distinct
morphologies. Cell counts for healthy (living), apoptotic, or necrotic cells were obtained from the
same treatment in duplicate wells and from three different fields for each well. Counting of the cells
was measured according to their appearance then averaged and expressed as a percent of the total
cell number.
2.5. Examination of the Drug Delivery System Penetration Across an In Vitro BBB Model
The lyophilised powders of both AEP-K-FP and the free drug (FP) were dissolved in the FBS-free,
phenol-free culture media in a concentration of 200 µM. Quantitative analysis of penetration for
the free-drug and drug-attached delivery system was undertaken using HPLC (Agilent technology,
Stockport, UK). The analysis was carried out using a hydrophobic C18 column (150 × 4.6 mm) at
25 ◦C and 20 µL of injection volume. The flow rate used was 0.6 mL/min, while the UV-detection
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wavelength was 248 nm, which is the λmax of FP [9]. The HPLC mobile phase solvents consisted of
water/acetonitrile in which the gradient of eluent was run from 75:25 to 25:75 water: acetonitrile over
20 min. The standard curve for each molecule was obtained to calculate the percentage of the amount
that transported across the in vitro BBB model.
To establish an in vitro BBB model, bEnd.3 cells were seeded on microporous membrane of
12-transwell inserts with complete culture media in a routine manner. Trans-endothelial electrical
resistance (TEER) between apical and basolateral chambers was measured using an Evom voltometer
(Sarasota, FL, USA) to determine the day of maximum values indicating tight junction formation, as
previously described [18].
In addition, paracellular permeability of this model was investigated using sucrose as a marker,
which was measured by the glucose oxidase (GOD)/invertase method, where its low permeability
indicated the tightness of the barrier [48]. The cells were cultured on transwell inserts (membrane of
0.4 µM pore size, Fisher Scientific, Loughborough, UK) to confluence, then treated with 1 mL solution
of sucrose/phosphate buffer saline (PBS) at a concentration of 2 mg/mL. After 15 and 30 min, samples
were collected from the lower chambers. In separate microcentrifuge tubes, 5 µL of sample, 85 µL
distilled water (DW), and 10 µL invertase /DW solution (of 10 mg/mL concentration) (Sigma Aldrich,
Gillingham, UK) were added. Control tubes that contained only PBS instead of the sample were
also included.
The tubes were placed in a water bath at 55 ◦C for 10 min, then 200 µL of GOD reagent (Sigma
Aldrich, Gillingham, UK) was added and the tubes were again placed in a water bath at 37 ◦C. After
15 min, the tubes were removed, and 10 µL of phenol solution was added to be incubated at room
temperature for 5 min. Samples were taken in duplicate and the absorbance was read at 490 nm using
a spectrophotometer. A calibration curve was constructed utilising standard sucrose solutions to
determine the sucrose concentration in the samples.
2.6. Quantification of γ-Secretase Enzyme Activity
The investigation is based on sandwich enzyme-linked immunosorbent assay (ELISA) technology
using a γ-secretase enzyme kit (Abbexa Ltd., Cambridge, UK). After confluence, C6 glial cells were
treated with 200 µM FP or AEP-K-FP / F-12K solution. Wells containing untreated C6 cells were
also included as a control. After 4 h of incubation, cells were washed and lysed to be centrifuged,
and the supernatant was collected for assaying the γ-secretase activity immediately, according to kit
instructions. Data were expressed as pg/mL, following kit instructions.
2.7. Drug Release
The AEP-K-FP was analysed for the hydrolysis of the amide linkage that coupled the drug
molecules to the peptide carrier as well as its amino acids residues. This hydrolysis of the complex was
evaluated in an acidic solution mimicking the lysosomal pH conditions that are likely to be found in an
inflamed tissue such as that of AD-affected brain tissue. The acidic buffer solution was prepared using a
phthalate solution, according to manufacturer’s instructions (Thomas Scientific, Swedesboro, NJ, USA),
to obtain a final pH of 4.5. The AEP-K-FP was dissolved in this buffer solution at a concentration
of 200 µM and incubated at static conditions for 24 h, 37 ◦C. Samples were collected and analysed
by HPLC.
2.8. Statistical Analysis
Mean values and standard deviation (SD) were calculated from the number of readings (n) from
each experiment. Results were statistically analysed using one-way ANOVA with Tukey’s tests.
Significant difference was identified by a P value < 0.05.
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3. Results
3.1. Characterisation of AEP-Functionalised FP-Delivery System
The mass spectra showed the successful synthesis of the AEP-K-FP with peaks corresponding
to the charged form of the expected MW, 1932 Da (Figure 2). Other peaks appearing in the spectra
were attributed to the ionisation of the molecule and to the solvent or machine noise, as well as to the
sodium salts formed due to interaction of ions with glass vessels [49].
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confirming the attachment of the drug to the peptidic nanocarrier (Figure 3).
Nanomaterials 2020, 10, x FOR PEER REVIEW 7 of 18 
 
2.8. Statistical Analysis 
M an values and standard deviation (SD) were calculated from the number of readings (n) from 
each experiment. Results were statistically analysed using one-way ANOVA with Tukey’s tests. 
Signific nt difference was identified by a P value < 0.05. 
3. Results 
3.1. Characteri ation of AEP-Functionalised FP-Delivery System 
The m ss spectra showed the successful synthesis of the AEP-K-FP with pe ks corresponding to 
the charged for  of the ex ected MW, 1932 D  (Figure 2). Other peaks appearing in the spectra were 
attributed to the ionisation f the molecule and to the solvent or machine noise, as well as to the 
sodium salts formed due to interaction of ions with glass vessels [49]. 
FTIR analysis showed the shifting of peaks caused by the formation of an amide linkage at 3200 
cm-1 and 1640 cm-1 and appearance of an aromatic ring peak of FP in the FP-linked AEP-K, confirming 
the attachment of the drug to the peptidic nanocarrier (Figure 3). 
 
Figure 2. Mass spectra of AEP-K-FP shows the dominant peak (645 with triple positive charge) of 
intensity 6.9 × 103 refers to the theoretical MW (m/z = (1932 + 1.008 × 3)/3). Alternatively, the peaks 484 
with quaternary charge at 3 × 103 intensity and 967 with double charge at 1.7 × 103 intensity represent 
the related ions of AEP-K-FP (m/z = (1932 + 1.008 × 4)/4 and m/z = (1932 + 1.008 × 2)/2, respectively. 
 
Figure 3. FTIR spectra of drug (FP) alone, peptide (AEP), and AEP-K-FP. The spectra show shifting 
peaks due to the formation of peptide linkages at 3200 and 1646 cm-1. The FP spectrum shows a strong 
carbonyl band at 1700 cm−1, which represents its COOH functional group that disappears in the AEP-
K-FP spectrum due to amide linkage formation. In addition to the appearance of a new peak at 782 
Figure 3. FTIR spectra of drug (FP) alone, peptide (AEP), and AEP-K-FP. The spectra show shifting
peaks due to the formation of peptide linkages at 3200 and 1646 cm−1. The FP spectrum shows a
strong carbonyl band at 1700 cm−1, which represents its COOH functional group that disappears in the
AEP-K-FP spectrum due to amide linkage formation. In addition to the appearance of a new peak at
782 cm−1, it corresponds to the aromatic ring of FP with its C=C peak at 910 cm−1 in the AEP-K-FP
spectrum, which confirms the FP attachment to the peptide.
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3.2. Cytotoxicity
An MTT assay was carried out on confluent bEnd.3 and HUVEC cells after 24 and 48 h of treatment
with increasing concentrations of the AEP-K-FP. The results showed no reduction in cell metabolic
activity by giving values more than 70% in relation to the control untreated cells (Figure 4), and all
values were within acceptable cytotoxic range (International-Standards 2009). The results suggest that
AEP-K-FP was not toxic to either cell phenotypes, even at the highest concentration used (400 µM)
they were 78.7% and 76.8% in bEnd.3 at 24 and 48 h, respectively, whereas for those with HUVEC, they
were 83% and 80.2% after 24 and 48 h of treatment, respectively. In addition, the statistical analysis
showed no significant differences (P > 0.05) between the corresponding concentrations after 24 or 48 h
of exposure.
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No cytotoxicity was found when LDH analysis was performed in the same range of concentration
used for the MTT experiments. Values of LDH release were less than 50% in relation to the positive
controls with a significant difference at P < 0.001. The highest values of LDH release after 24 and 48 h
of treatment with AEP-K-FP were seen at a concentration of 400 µM for both cultured cells, with no
significant differences (P > 0.05) between each other at corresponding concentrations (Figure 4).
HPI staining of brain endothelial cells following treatment with AEP-K-FP revealed no cytotoxicity
consistently with the results obtained from both MTT and LDH experiments. The percentages of
healthy cells at the concentration range used (100, 300, and 400 µM) were never lower than 91%.
While the values of apoptotic and necrotic cells did not exceed 4.7% and 3.4%, respectively, and
no significant differences (P > 0.05) from the control samples at any concentrations were observed
(Figure 5).
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3.3. Penetration of the Drug Delivery System Across an In Vitro BBB Model
The penetration of both the free drug and the RMT-driven drug delivery system following 1h and
4 h of incubation was evaluated by a BBB model using bEnd.3 cultured as monolayers on a transwell
system, which was created and validated using TEER measurement, as reported in a previous work [18].
To verify that this cultured monolayer is devoid of paracellular transport for solutes, sucrose was used
as a permeability marker. The standard curve of a series of dilutions of the sucrose solution was carried
out to quantify the amount of sucrose that penetrated across the membrane, and the percentage of
permeability was calculated, as shown in Table 1.
Table 1. Values of sucrose permeability.
Time Readings
% S crose Permeability (Mean ± SD)
Membrane HUVEC bEnd.3
15 min 4 44.7 ± 4.1 19.6 ± 2.7 6.2 ± 1.4
30 min 4 46.8 ± 3.6 32.2 ± 3.2 9.4 ± 1.8
After a 15 min incubation of the cultured cells (bEnd.3 and HUVEC) in the sucrose solution on
transwell inserts, only 6.2% of the initial amount passed across the bEnd.3 monolayer in comparison
to 19.6% for that with HUVEC, whereas the amount did not increase more than 9.4% and 32.2%,
respectively, after 30 min. The membrane alone showed free sucrose transport to give equilibrium
between the two chambers. These results demonstrated the resistance of the forme bEnd.3 monolayer
to paracellular solute transport.
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A series of dilutions of both the free drug and the AEP-K-FP dissolved in phenol-free DMEM
solution were analysed by HPLC, and the relative standard curves were obtained (Figure 6).
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The percentage of the AEP-K-FP permeated across this model increased more than 6 times (16.3%)
after 1 h, and 4 times (35.9%) after 4 h with significant differences (P < 0.001) from that of free-FP
levels, which did not exceed 2.7% and 8.5% of the applied concentration after 1 h and 4 h, respectively
(Figure 7). It is worth mentioning that the AEP-K-FP has 2 additional moles of drug, hence this can
increase the amount of drug that is released upon dissociation of the linkage.
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However, the decrease in the enzyme activity induced by AEP-K-FP was not as much as that observed
with free drug (P < 0.05) (Table 2).
Table 2. Quantification of γ-secretase enzyme after exposure to free FP and AEP-K-FP.
Factor Readings Mean ± SD pg/mL P-Value to FP P-Value to Control
Control 6 28.43 ± 8.32
< 0.05FP 6 8.20 ± 3.80
AEP-K-FP 6 14.60 ± 3.51 < 0.05 < 0.05
3.5. Degradation Analysis and Drug Release
To investigate the hydrolysis of the AEP-functionalised FP-delivery system and the release of the
attached drug in an environment mimicking the inflamed tissue typical of AD conditions, an acidic
buffer was used. Qualitative HPLC analysis of the AEP-K-FP in this medium showed the appearance
of various peaks in the spectrum suggesting the hydrolysis of the peptide into different products,
with a clear peak representing the free drug (Figure 8). The remaining detected peaks in the spectrum
were likely to be identified as amino acid residues or shorter peptides sequences deriving from the
hydrolysis process. This was suggested by their earlier elution due to their lower MW and reduced
hydrophobicity (Figure 8). Quantitative analysis of the peaks showed that the percentage of hydrolysed
FP was 69.2% out of the total amount of AEP-K-FP (Table 2).
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4. Discussion
The transport, cellular uptake, and performance of drugs at their target sites are significant
challenges in the treatment of AD and other NDs due to their limited penetration of the BBB [3]. Similar
to other drugs, FP is unable to permeate throu h the BBB at therapeutically effective concentrations.
The delivery of potential therapeutic agents, therefore, requires active-transport mechanisms to enable
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the transport of these molecules across the BBB. Several strategies to improve the delivery to the
CNS have been developed including local injection or BBB surgical opening, facilitating the drug
permeability and targeting delivery to the brain [27]. Improving permeability of drugs or other
substances to cross the BBB via regulated transcytosis is deemed an attractive strategy to enable the
passage of macromolecular complexes, which are not normally achieved [23].
In the recent years, brain drug delivery has focused on pathways that can exploit endogenous
receptors on BBB endothelia in promoting the passage of specific particles by RMT [37]. This pathway
employs the endothelial vesicular trafficking mechanism to convey molecules from blood to brain.
With an appropriate receptor-targeting ligand, RMT system can shuttle numerous drugs into the brain
noninvasively [50]. One of the crucial areas of concern in RMT is to find receptors that are (a) selective
to the BBB vasculature and (b) highly expressed in the desired site. An additional challenge is to find
ligands that are capable of taking advantage of these receptors in the transcytosis for drug delivery [23].
Upregulation of the LDL receptors at the BBB region in comparison with other endothelia supports
this hypothesis via ligand recognition. Previously, studies have shown that the LDLr participated in
the transport of a wide range of molecules from the blood to the brain following functionalisation of
delivery systems with the binding site of the ApoE peptide [29,51].
In the present study, FP molecules were coupled to a specifically designed peptide nanocarrier,
whereby the FP molecules were presented at the terminal molecular branches of a lysine added to
the known AEP-mimicking peptide sequence (the ApoE 141-150 amino acids sequence) that has been
shown to be able to bind LDLr [37]. A microwave-driven SPPS was used as an efficient method of
synthesis. The AEP-K-FP synthesis was obtained by employing typical Fmoc-protected amino acid
coupling chemistry. In order to overcome some of drawbacks associated with long chain peptides,
such as intermolecular aggregation or truncated sequence [52], a capping step was introduced after
each amino acid coupling. Consequently, any short chain sequences formed could be easily removed
leading to a purer product, as confirmed by the MS and HPLC results of this work.
The chosen chemical modification with a lysine terminal allows a branching design of the
nanocarrier that can be modified in a versatile manner depending on the targeted applications
(e.g., drug and gene delivery) [53]. A previous study has shown an efficient bi-functionalisation of
hyperbranched dendrimers with carboxymethyl PEG5000 and folic acid leading to high cell-specific
targeting and more folic acid delivering [54]. Another study has shown that dendrimers functionalised
with Tf or Lf as ligands enhanced the delivery of doxorubicin to the brain in comparison to the
unfunctionalised carriers [55]. In addition the brain permeability of the opioid, peptide OX26
was potentiated when the molecule was loaded onto a functionalised dendrimer [56], while the
angiopep-functionalised dendrimer has been used efficiently in gene delivery [17].
Nanocarriers’ biocompatibility is a prerequisite for its use in clinics [57]. In this work, when the
AEP-K-FP was tested at concentrations up to 400 µM, it did not show any significant decrease in cellular
metabolic activity in MTT assay or a significant effect on cellular membrane integrity, according to the
LDH assay, after 24 and 48 h exposure periods. Hence, these results show that there is no significant
cytotoxic effect on endothelial cells such as bEnd.3 and HUVEC cell lines. Cell death assessment using
HPI staining also confirmed the above finding, where the cells treated with the FP-delivery system
showed very low levels of apoptosis and necrosis. It can be speculated that this is due to the ability of
the AEP-K-FP to cross the cells via transcytosis process without affecting their nuclei [47].
At the same time, the observation regarding the cytotoxic effect observed at higher concentrations
may be attributed to the increase in permeability across the cell membrane via RMT causing excessive
damage of the plasmalemma with consequent loss of the mitochondrial functions and overall cell
viability [58]. Indeed, the results are consistent with results of previous studies, which demonstrated
that the toxicity of ApoE peptide increases at relatively high concentrations [33].
Overall findings indicate that the noncytotoxicity of the AEP-K-FP at the concentration values
used is in agreement with other studies that focussed on the effect of ApoE and ApoE-decorated
nanoliposomes on brain endothelial cells up to 48 h of incubation [37]. Another study demonstrated
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that there was no cytotoxic effect of ApoE-modified NPs when incubated with bEnd.3 cells at different
concentrations for 24 h [31].
The BEnd.3 cell line has widely been utilised as an in vitro model of drug-delivery-system
penetration across the BBB, with data showing its ability to mimic sufficiently the in vivo
conditions [59–61]. In this paper, a TEER analysis confirmed that the model was suitable to assess the
transport potential of the AEP-K-FP across the BBB, as the data collected confirmed those obtained
in a previous work [18]. Further validation of the model was performed to ascertain paracellular
permeability. The permeability of the bEnd.3 to sucrose was significantly lower than that of HUVEC
when these cells were cultured in a transwell system, the polycarbonate filter of the system showing no
additional barrier effect. It was suggested that the sucrose permeability decreased in brain endothelial
cell cultures that had reached confluence due to the formation of tight junctions; this was deemed
an acceptable indicator of BBB model validity [62]. Another research has showed a limited sucrose
permeability using the immortalised brain capillary endothelial cells [63,64].
Penetration of free FP was found to be less than 9% of its initial payload concentration, indicating
levels of permeability similar to those observed in a previous study and not sufficient to induce a
pharmacological effect on target cells [9]. FP permeability across the endothelial layer was improved
when the drug was integrated in the carrier structure reaching a four-fold increase. It is worth
highlighting that the percentage of permeability does not reflect the amount of the drug delivered to
the target tissue, as each carrier bears two FP molecules that could eventually be released from delivery
system upon hydrolysis of the peptide carrier. The results of the synthesised drug delivery system
demonstrated its crossing of the bEnd.3 monolayer culture suggesting that it can be internalised and
then undergo exocytosis following an RMT pathway. This interpretation of the data are supported by
previous observations that AEP-decorated carrier systems cross the BBB model via RMT mechanism
through their selective binding to the membrane LDLr [31,65].
The BBB endothelium is known for its relatively high level of LDLr expression in relation
to other tissues [3,51]. This receptor mediates the transcytosis of circulating lipoproteins into the
brain. ApoE is one of the known ligands for this receptor, and its amino acid sequence 141–150 is
considered the recognition domain leading to the protein/receptor complex internalisation. When
used to functionalize NP and liposomes, the ApoE-derived peptide facilitates the uptake of these
types of carriers, and it has been proposed for applications, such as brain cancer treatment [28,66].
Likewise, through confocal microscopy and flow cytometry, our previous work has proven the increased
transcytosis of AEP-modified branched nanocarrier by brain endothelial culture when compared to a
nonmodified branched nanocarrier, suggesting that drugs integrated into these branched nanocarriers
could indeed reach the target tissue at therapeutic doses [40].
Numerous drugs have efficiently crossed the BBB using ApoE-functionalised delivery system,
such as dalargine, curcumin, and doxorubicin [28,37,65]. In this work, the AEP-functionalised delivery
system has significantly enhanced the FP crossing of a brain endothelial barrier at concentrations higher
than those found on a similar system based on AMT (RMT = 36%, AMT = 12%) [18], demonstrating
the potential advantage in adopting RMT-driven FP delivery system in AD treatment.
In addition, the reported higher expression of the LDLr on brain endothelial is likely to increase
the delivery of the required drug doses to the target tissue, thus minimizing unwanted effects of
the drug on other organs and reducing the need for the administration of high and frequent doses
potentially causing side effects.
FP has been found to act primarily on the PSEN (presenilin) site of the γ-secretase complex in
turn prevent formation of neurotoxic Aβ42 isomer during APP cleavage [8,67,68]. The present study
also evaluated FP effect on the γ-secretase enzyme activity of glial C6 cells line when coupled to the
nanocarrier. Likewise, for the previously studied AMT-driven FP-functionalised nanocarrier, the results
revealed that the conjugated drug still retained its action in modulatory activity of γ-secretase, albeit at
a significantly lower level (P < 0.05). The reduced activity found could be explained by the steric
hindrance of the large size molecule and/or by the spatial arrangement of the functional group which
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might change its reactivity. Several studies have previously supported this explanation in which drugs
lacked their usual efficiency upon conjugation to carriers due to steric hindrance [69,70]. Instead,
some other drugs were able to maintain their activity, while they still attach to the carriers [70].
To provide data of drug activity in the long term, the degradation of AEP-K-FP was investigated
using HPLC analysis proving that the hydrolysis of the nanocarrier in conditions similar to that of
the AD inflamed tissue can liberate FP molecules, thus adding the potential advantage of achieving a
more protracted effect on the target tissue. Studies have reported that dendrons or peptides with such
backbones are completely degraded into their building monomers, in turn releasing their payloads
including the drug [71–73]. Furthermore, it has been shown that these biodegradable units not only
help in the final dissociation of the carriers but also can reduce their toxicity through a release of lower
doses by enzyme-driven proteolysis [17,74]. The peptide fragments of the carrier can be subsequently
metabolised and eliminated from the body [75].
A time-course analysis of the drug liberation from the nanocarrier upon hydrolysis was not
performed in this study as, albeit reduced, the drug retained its activity when bound to the nanocarrier,
and it was not completely released in a free form after 24 h of incubation in the lysosomal-mimicking
medium that is the recommended FP administration timescale [12]. In other words, as doses are
likely to be administered to the patients daily, the improved BBB penetration and the activity of both
conjugated and free FP should ensure adequate levels of administered FP at the target tissue.
The coupling of the drug to the peptide-based nanocarrier did not alter the ApoE-mimicking
peptide function in promoting RMT, and predisposed the FP liberation through its grafting to the
branching lysine amino groups. The latter has been demonstrated by previous studies that revealed
full pharmacological action of drugs, such as methotrexate and testosterone upon degradation of the
amide linkages or arms [70].
It has also been shown that dendrons or peptides can protect drugs against systemic degradation,
enhancing the stability of the complex during the blood circulation [71,76,77]. It can be speculated that,
as FP and other NSAIDs form complexes with plasma proteins when in free form, their complexation
with the nanocarriers can also contribute to increase the amounts reaching the target tissue rather than
being neutralised by their complexation with host plasma proteins [78]. In turn, this protective effect
would reduce the need for relatively high doses [79].
Previous attempts to improve brain FP permeability, which were either by its entrapment in
PEG-micelles [80] or by embedding FP in NP [9], did not show an increase in permeability as high as
that observed in the case of the AEP-K-FP delivery system. In comparison to these studies, the present
system provides the advantages of reduced molecular weight, low cytotoxicity, and long-term drug
liberation—properties difficult to achieve by drug entrapping or encapsulation methods [81,82].
Together with the potential scaling-up of the synthesis of these nanocarriers, the findings of this study
offer an attractive nanomedicine system for the treatment of AD by FP.
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